Real-world effectiveness of J&J's COVID-19 vaccine

Key clinical point: Johnson & Johnson's (J&J) adenoviral vector COVID-19 vaccine (Ad26.COV) was effective in preventing COVID-19 and severe outcomes in a real-world setting.

Major finding: The incidence rate ratio of COVID-19 in the Ad26.COV-vaccinated vs unvaccinated cohort was 0.26 (95% CI, 0.20-0.34), corresponding to an effectiveness of 73.6% (95% CI, 65.9%-79.9%). Ad26.COV recipients also had a lower risk for hospitalization (odds ratio [OR], 0.32; P = .00028) and ICU admissions (OR, 0.00; P = .001) compared with unvaccinated individuals.

Study details: The data come from an analysis of 8,889 individuals vaccinated with Ad26.COV and 88,898 unvaccinated matched controls.

Disclosures: No information on funding was available. J Corchado-Garcia, D Zemmour, T Hughes, P Lenehan, C Pawlowski, JC O’Horo, AD Badley, MD Swift, T Wagner, and V Soundararajan reported relationships with various pharmaceutical companies. The remaining authors declared no conflict of interests.

Source: Corchado-Garcia J et al. JAMA Netw Open. 2021 Nov 2. doi: 10.1001/jamanetworkopen.2021.32540.

Key clinical point: Johnson & Johnson's (J&J) adenoviral vector COVID-19 vaccine (Ad26.COV) was effective in preventing COVID-19 and severe outcomes in a real-world setting.

Major finding: The incidence rate ratio of COVID-19 in the Ad26.COV-vaccinated vs unvaccinated cohort was 0.26 (95% CI, 0.20-0.34), corresponding to an effectiveness of 73.6% (95% CI, 65.9%-79.9%). Ad26.COV recipients also had a lower risk for hospitalization (odds ratio [OR], 0.32; P = .00028) and ICU admissions (OR, 0.00; P = .001) compared with unvaccinated individuals.

Study details: The data come from an analysis of 8,889 individuals vaccinated with Ad26.COV and 88,898 unvaccinated matched controls.

Disclosures: No information on funding was available. J Corchado-Garcia, D Zemmour, T Hughes, P Lenehan, C Pawlowski, JC O’Horo, AD Badley, MD Swift, T Wagner, and V Soundararajan reported relationships with various pharmaceutical companies. The remaining authors declared no conflict of interests.

Source: Corchado-Garcia J et al. JAMA Netw Open. 2021 Nov 2. doi: 10.1001/jamanetworkopen.2021.32540.

Key clinical point: Johnson & Johnson's (J&J) adenoviral vector COVID-19 vaccine (Ad26.COV) was effective in preventing COVID-19 and severe outcomes in a real-world setting.

Major finding: The incidence rate ratio of COVID-19 in the Ad26.COV-vaccinated vs unvaccinated cohort was 0.26 (95% CI, 0.20-0.34), corresponding to an effectiveness of 73.6% (95% CI, 65.9%-79.9%). Ad26.COV recipients also had a lower risk for hospitalization (odds ratio [OR], 0.32; P = .00028) and ICU admissions (OR, 0.00; P = .001) compared with unvaccinated individuals.

Study details: The data come from an analysis of 8,889 individuals vaccinated with Ad26.COV and 88,898 unvaccinated matched controls.

Disclosures: No information on funding was available. J Corchado-Garcia, D Zemmour, T Hughes, P Lenehan, C Pawlowski, JC O’Horo, AD Badley, MD Swift, T Wagner, and V Soundararajan reported relationships with various pharmaceutical companies. The remaining authors declared no conflict of interests.

Source: Corchado-Garcia J et al. JAMA Netw Open. 2021 Nov 2. doi: 10.1001/jamanetworkopen.2021.32540.